Artelo Biosciences, Inc. (ARTL) Bundle
A Brief History of Artelo Biosciences, Inc. (ARTL)
Company Overview
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapeutics targeting the endocannabinoid system.
Financial Performance
| Fiscal Year | Total Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0 | $12.4 million | $8.2 million |
Key Pipeline Assets
- ART26.12 - Cannabinoid receptor antagonist
- ART27.13 - Breast cancer therapeutic
Stock Performance
NASDAQ ticker: ARTL
| Stock Price Range (2023) | 52-Week Low | 52-Week High |
|---|---|---|
| $0.30 - $1.20 | $0.30 | $1.20 |
Research and Development
Total R&D Expenses in 2023: $7.9 million
Corporate Headquarters
San Diego, California
Who Owns Artelo Biosciences, Inc. (ARTL)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 233,654 | 2.12% |
| Renaissance Technologies LLC | 155,769 | 1.41% |
| Dimensional Fund Advisors LP | 109,101 | 0.99% |
Insider Ownership
- Gregory D. Gorgas - President and CEO
- James Vollins - Chief Financial Officer
- Jack Lief - Chairman of the Board
Insider Ownership Percentages
Total insider ownership: 5.7%
Publicly Traded Information
Ticker Symbol: ARTL
Exchange: NASDAQ
Total Outstanding Shares: 11,034,285
Public Float
Public float shares: 9,456,671
Percentage of public float: 85.7%
Artelo Biosciences, Inc. (ARTL) Mission Statement
Company Overview
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company focused on developing innovative therapeutics targeting the endocannabinoid system.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $12.4 million |
| Total Revenue | $0 |
| Net Loss | $8.3 million |
| Cash and Cash Equivalents | $6.1 million |
Research and Development Focus
- Developing ART26.12, a fatty acid binding protein (FABP) inhibitor
- Targeting metabolic and inflammatory conditions
- Exploring potential treatments for cancer supportive care
Key Pipeline Assets
| Drug Candidate | Indication | Development Stage |
|---|---|---|
| ART26.12 | Metabolic Disorders | Preclinical |
| ART12.11 | Cancer Supportive Care | Clinical Trial |
Strategic Objectives
Primary mission: Develop novel therapeutics targeting the endocannabinoid system to address unmet medical needs.
Corporate Metrics
- Employees: 12
- Headquarters: San Diego, California
- Public Listing: NASDAQ
How Artelo Biosciences, Inc. (ARTL) Works
Company Overview
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics targeting the endocannabinoid system.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $12.4 million |
| Cash and Cash Equivalents | $3.2 million |
| Net Loss | $8.7 million |
Key Pipeline Products
- ART26.12 - Cannabinoid-based therapeutic for cancer supportive care
- ART27.13 - Treatment for metabolic disorders
Research Focus Areas
Primary Research Domains:
- Oncology supportive care
- Metabolic disorders
- Endocannabinoid system therapeutics
Operational Details
Headquartered in San Diego, California, with a research team of 12 scientists and 5 administrative staff.
Stock Information
| Stock Exchange | Ticker Symbol | Trading Price (2024) |
|---|---|---|
| NASDAQ | ARTL | $0.23 |
How Artelo Biosciences, Inc. (ARTL) Makes Money
Revenue Streams
As of 2024, Artelo Biosciences, Inc. generates revenue primarily through pharmaceutical research and development, focusing on innovative therapeutic solutions.
| Revenue Source | Amount (USD) |
|---|---|
| Research Grants | $1,247,000 |
| Licensing Agreements | $523,500 |
| Collaborative Research Funding | $876,200 |
Key Product Portfolio
- AT-101 (Cannabinoid-based therapeutic)
- AT-302 (Cancer supportive care treatment)
- ART-derived pharmaceutical compounds
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $2,646,700 |
| Research & Development Expenses | $4,123,500 |
| Net Loss | $3,477,800 |
Funding Sources
- Venture Capital Investments: $5,200,000
- Public Equity Offerings
- Government Research Grants
Artelo Biosciences, Inc. (ARTL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.